|
ChemGenex Pharmaceuticals Limited (ASX: CXS, Nasdaq: CXSP), based in
Melbourne, Australia and Menlo Park, California, U.S.A., and Stragen Pharma
S.A., based in Geneva, Switzerland, today announced an international alliance to
accelerate the clinical development of ChemGenex's lead anti-cancer therapeutic,
CeflatoninĀ®. CeflatoninĀ® is currently in a Phase 2 Clinical Trial at the M.D.
Anderson Cancer Center in Houston, Texas treating chronic myeloid leukemia (CML)
patients who are resistant to GleevecĀ®.
|
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
